Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.
Atomo Diagnostics has scheduled the release of its Q2 FY26 financial results for Wednesday, 28 January 2026, and will host an investor and analyst webinar briefing on the same day at 2:00 pm AEDT, led by Managing Director and CEO John Kelly. The company is directing investors to pre-register online and use its Investor Hub to submit questions and comments in advance, underlining a continued focus on proactive engagement with the market and transparency around its financial and operational performance.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that develops and supplies patented, integrated rapid diagnostic test devices to the global diagnostics market. Its products are designed to simplify testing procedures, enhance usability and improve reliability for rapid point-of-care and at-home testing, with commercialised solutions and supply agreements in place for infectious disease testing including COVID-19, HIV, viral versus bacterial differentiation and female health applications.
Average Trading Volume: 1,183,764
Technical Sentiment Signal: Buy
Current Market Cap: A$29.98M
See more data about AT1 stock on TipRanks’ Stock Analysis page.